Published Papers & Misc - TANAKA Shinji

Division display  141 - 160 of about 233 ／  All the affair displays >>

  1. Furuyama T, Tanaka S, Shimada S, Akiyama Y, Matsumura S, Mitsunori Y, Aihara A, Ban D, Ochiai T, Kudo A, Fukamachi H, Arii S, Kawaguchi Y, Tanabe M. Proteasome activity is required for the initiation of precancerous pancreatic lesions Scientific Reports. 2016.05; 6 27044. ( DOI )

  2. 4) Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, Sayuri Nitta S, Watanabe T, Otani S, Taniguchi M, Goto F, Nagata H, Kaneko S, Tasaka-Fujita M, Nishimura-Sakurai Y, Azuma S, Itsui Y, Nakagawa M, Tanabe M, Takano S, Fukasawa M, Sakamoto M, Maekawa S, Enomoto N, Watanabe M. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. Journal of Gastroenterology. 2016.05; 51 (5): 473-486. ( DOI )

  3. Yamada N, Yasui K, Dohi O, Gen Y, Tomie A, Kitaichi T, Iwai N, Mitsuyoshi H, Sumida Y, Moriguchi M, Yamaguchi K, Nishikawa T, Umemura A, Naito Y, Tanaka S, Arii S, Itoh Y. Genome-wide DNA methylation analysis in hepatocellular carcinoma Oncology Reports. 2016.04; 35 (4): 2228-2236. ( DOI )

  4. Tanaka S.. Molecular pathogenesis and targeted therapy of pancreatic cancer. Annals of Surgical Oncology. 2016.02; Suppl (2): 197-205.

  5. 4) Katsuta E, Tanaka S, Mogushi K, Shimada S, Akiyama Y, Aihara A, Matsumura S, Mitsunori Y, Ban D, Ochiai T, Kudo A, Fukamachi H, Tanaka H, Nakayama K, Arii S, Tanabe M . CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells International Journal of Oncology. 2016.02; 48 (2): 657-669.

  6. Katsuta E, Tanaka S, Mogushi K, Shimada S, Akiyama Y, Aihara A, Matsumura S, Mitsunori Y, Ban D, Ochiai T, Kudo A, Fukamachi H, Tanaka H, Nakayama K, Arii S, Tanabe M.. CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells. Int J Oncol. . 2016.02; 48 (2): 657-669.

  7. Nakao K, Tanaka S, Miura T, Sato K, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M. A novel Aurora/VEGFR dual kinase inhibitor as treatment for hepatocellular carcinoma Cancer Science. 2015; 106 (8): 1016-1022.

  8. Okajima C, Arii S, Tanaka S, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanabe M. Prognostic role of Child-Pugh score 5 and 6 in hepatocellular carcinoma patients who underwent curative hepatic resection American Journal of Surgery. 2015; 209 (1): 199-205.

  9. Sakamoto A, Akiyama Y, Shimada S, Zhu WG, Yuasa Y, Tanaka S. DNA methylation in the exon 1 region and complex regulation of Twist1 expression in gastric cancer PLoS ONE. 2015; 10 (12): e0145630.

  10. Miura T, Ban D, Tanaka S, Mogushi K, Kudo A, Matsumura S, Mitsunori Y, Ochiai T, Tanaka H, Tanabe M. Distinct clinicopathological phenotype of hepatocellular carcinoma with EOB-MRI hyperintensity: association with gene expression signature American Journal of Surgery. 2015; 210 (3): 561-569.

  11. Matsunaga H, Tanaka S, Aihara A, Ogawa K, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Arii S, Tanabe M. A novel therapeutic combination targeting sequentially Aurora B and Bcl-xL in hepatocellular carcinoma Annals of Surgical Oncology. 2015; 22 (9): 3079-3086.

  12. Ban D, Kudo A, Ito H, Mitsunori Y, Matsumura S, Aihara A, Ochiai T, Tanaka S, Tanabe M, Itano O, Kaneko H, Wakabayashi G. The difficulty of laparoscopic liver resection Updates in Surgery. 2015; 67 (2): 123-128.

  13. Ban D, Kudo A, Irie T, Ochiai T, Aihara A, Matusmura S, Tanaka S, Tanabe M. Advances in reduced port laparoscopic liver resection Asian Journal of Endoscopic Surgery. 2015; 8 (1): 11-15.

  14. Tanaka S. Cancer stem cells as therapeutic targets of hepato-biliary-pancreatic cancers Journal of Hepato-Biliary-Pancreatic Sciences. 2015; 22 (7): 531-537.

  15. Watanabe Y, Yamamoto H, Oikawa R, Toyota M, Yamamoto M, Kokudo N, Tanaka S, Arii S, Yotsuyanagi H, Koike K, Itoh F. DNA methylation at hepatitis B viral integrants is associated with methylation at flanking human genomic sequences Genome Research. 2015; 25 (3): 328-337.

  16. Yasui K, Konishi C, Gen Y, Endo M, Dohi O, Tomie A, Kitaichi T, Yamada N, Iwai N, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Tanaka S, Arii S, Itoh Y. EVI1, a target gene for amplification at 3q26, antagonizes TGF-beta-mediated growth inhibition in hepatocellular carcinoma Cancer Science. 2015; 106 (7): 929-937.

  17. Kudo A, Matusmura S, Ban D, Irie T, Ochiai T, Tanaka S, Arii S, Tanabe M.. Does the preoperative alpha-fetoprotein predict the recurrence and mortality after hepatectomy for hepatocellular carcinoma without macrovascular invasion in patients with normal liver function? Hepatol. Res.. 2014.12; 44 (14): E437-E446. ( PubMed, DOI )

  18. Matsunaga H, Tanaka S, Aihara A, Ogawa K, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Arii S, Tanabe M.. A Novel Therapeutic Combination Sequentially Targeting Aurora B and Bcl-xL in Hepatocellular Carcinoma. Ann. Surg. Oncol.. 2014.12; ( PubMed, DOI )

  19. Kudo A, Tanaka S, Ban D, Matsumura S, Irie T, Ochiai T, Nakamura N, Arii S, Tanabe M.. Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis. J. Gastroenterol.. 2014.09; 49 (9): 1352-1361. ( PubMed, DOI )

  20. Kudo A, Tanaka S, Matsumura S, Ban D, Irie T, Ochiai T, Nakamura N, Arii S.. Anatomic resection reduces the recurrence of solitary hepatocellular carcinoma ≤5 cm without macrovascular invasion. Am. J. Surg.. 2014.06; 207 (6): 863-869. ( PubMed, DOI )

< PREV - NEXT >

To the head of this page.▲